

Most Read This Week
- Bempegaldesleukin Plus Nivolumab in First-Line Renal Cell Carcinoma
- 69-Year-Old Man Diagnosed With RCC Who Experienced Late-Onset Metastasis
- HRQoL Outcomes in Patients With Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib
- Association of Early Changes in Dual-Layer Detector CT Parameters With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma
- Effect of BMI on Survival Outcome of Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
Recently Updated
- 69-Year-Old Man Diagnosed With RCC Who Experienced Late-Onset Metastasis
- Bempegaldesleukin Plus Nivolumab in First-Line Renal Cell Carcinoma
- Effect of BMI on Survival Outcome of Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
- Association of Early Changes in Dual-Layer Detector CT Parameters With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma
- HRQoL Outcomes in Patients With Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib